Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...

A new study published online in the Journal of Intensive Medicine on June 17, 2025, highlights early and dynamic alterations in lymphocyte subsets following sepsis in elderly patients and their ...

CD3 (including its subunits CD3ε, CD3δ, CD3γ, and CD3ζ) is the central component of the TCR-CD3 complex and is crucial for recognizing T cells and responding to antigens. Every subunit of CD3 has ...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of ...

Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer Tumor tissue from 868 patients in the QUASAR ...

A phase 1 trial of a human thymus-expressed apoptosis factor in patients with advanced solid tumors: Interim report. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract ...

The RAINIER study continues to enroll patients across additional dose levels. Mipletamig's design leverages Aptevo's ADAPTIR (TM) platform to deliver targeted T-cell engagement with the goal of ...

Roche’s FDA approval of Lunsumio VELO as a one-minute subcutaneous bispecific therapy for relapsed or refractory follicular lymphoma marks a meaningful advance in reducing treatment burden while ...

This article is based on a poster originally authored by Weiping Sun, Xing Zhang, Zhaolu Yan, Chen Yu, Spencer Chiang, and Tianfu Zhang. Immunotherapy is an advanced and widely used treatment due to ...

Although the readout was only from four multiple myeloma patients, attendees at the meeting wondered at how far the CAR T-cell therapy field has come.